Dosimetric characterization of the GammaClip™ 169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection
Purpose: A novel169Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production & Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was cha...
Gespeichert in:
Veröffentlicht in: | Medical physics (Lancaster) 2013-08, Vol.40 (8), p.080701-n/a |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose:
A novel169Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production & Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was characterized in terms of “Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO” by Perez-Calatayud
et al.
[Med. Phys.
39, 2904–2929 (2012)]10.1118/1.3703892
using the updated AAPM Task Group Report No. 43 formalism.
Methods:
Monte Carlo calculations were performed using Monte Carlo N-Particle 5, version 1.6 in water and air, the in-air photon spectrum filtered to remove photon energies below 10 keV in accordance with TG-43U1 recommendations and previously reviewed169Yb energy cutoff levels [D. C. Medich, M. A. Tries, and J. M. Munro, “Monte Carlo characterization of an Ytterbium-169 high dose rate brachytherapy source with analysis of statistical uncertainty,” Med. Phys.
33, 163–172 (2006)]10.1118/1.2147767
. TG-43U1 dosimetric data, including S
K
,
$\dot D(r,\theta)$
D
̇
(
r
,
θ
)
, Λ, g
L
(r), F(r, θ), ϕ
an
(r), and
$\bar \phi _{an}$
ϕ
¯
a
n
were calculated along with their statistical uncertainties. Since the source is not axially symmetric, an additional set of calculations were performed to assess the resulting axial anisotropy.
Results:
The brachytherapy source's dose rate constant was calculated to be (1.22 ± 0.03) cGy h−1 U−1. The uncertainty in the dose to water calculations,
$\dot D(r,\theta)$
D
̇
(
r
,
θ
)
, was determined to be 2.5%, dominated by the uncertainties in the cross sections. The anisotropy constant,
$\bar \phi _{an}$
ϕ
¯
a
n
, was calculated to be 0.960 ± 0.011 and was obtained by integrating the anisotropy factor between 1 and 10 cm using a weighting factor proportional to r
−2. The radial dose function was calculated at distances between 0.5 and 12 cm, with a maximum value of 1.20 at 5.15 ± 0.03 cm. Radial dose values were fit to a fifth order polynomial and dual exponential regression. Since the source is not axially symmetric, angular Monte Carlo calculations were performed at 1 cm which determined that the maximum azimuthal anisotropy was less than 8%.
Conclusions:
With a higher photon energy, shorter half-life and higher initial dose rate169Yb is an interesting alternative to 125I for the treatment of nonsmall cell lung cancer. |
---|---|
ISSN: | 0094-2405 2473-4209 0094-2405 |
DOI: | 10.1118/1.4812675 |